VetSheet

Desoxycortone pivalate

Corticosteroid - MineralocorticoidSCDogsCats

Also known as: Zycortal Β· Desoxycortisone pivalate Β· DOCP

Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference

Initial dose 1.5-2.2 mg/kg (final dose can be between 1.0 and 2.7 mg/kg)SCΒ· long-acting (interval not specified in text)Β· Long-term replacement
β€” πŸ•

Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.

Dosing by species

🌎 NA β€” North America🌍 EU β€” Europe

Dogs

IndicationDoseRouteFrequencyDurationRegion
Primary hypoadrenocorticism (Addison's disease)Initial dose 1.5-2.2 mg/kg (final dose can be between 1.0 and 2.7 mg/kg)SClong-acting (interval not specified in text)Long-term replacement🌍 EU
  • Primary hypoadrenocorticism (Addison's disease): Many authorities start at the lower dose of 1.5 mg/kg SC, particularly in larger dogs.

Cats

IndicationDoseRouteFrequencyDurationRegion
Primary hypoadrenocorticism (Addison's disease)Initial dose 2.2 mg/kgSClong-actingLong-term replacement🌍 EU
  • Primary hypoadrenocorticism (Addison's disease): Experience is limited but higher doses seem to be needed.

Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.

Recording this consult? VetSheet's AI writes the drug, dose and duration straight into a structured visit note.See how VetSheet works

Overview

Long-acting, replacement therapy for mineralocorticoid deficiency in dogs and cats with primary hypoadrenocorticism (Addison's disease).

​Warning:​ It is critical that Addison's disease is definitively diagnosed before starting treatment.

​Warning:​ Any dog presenting with severe hypovolaemia, dehydration, pre-renal azotaemia, and inadequate tissue perfusion (Addisonian crisis) must be rehydrated with intravenous fluid (saline) therapy before starting treatment with this product.

​Clinical Pearl:​ Many dogs require lower doses than the authorized 2.2 mg/kg. Starting at 1.5 mg/kg SC is common, particularly in larger dogs, with final maintenance doses often ranging between 1.0 and 2.7 mg/kg. Use lower doses in patients with congestive heart disease, severe renal disease, primary hepatic failure, or oedema.

Mechanism of action

Acts as a mineralocorticoid replacement. It binds to mineralocorticoid receptors in the distal renal tubules β†’ increases sodium reabsorption and promotes potassium excretion β†’ restores electrolyte balance and maintains extracellular fluid volume and blood pressure.

Safety & warnings

Contraindications

  • None strictly listed, but use with caution in congestive heart disease, severe renal disease, primary hepatic failure, or oedema

Adverse effects

  • Pain on injection (rarely repeated in the same animal)
  • Polyuria
  • Polydipsia
  • Hypokalaemia (with overdose)
  • Vomiting
  • Anorexia
  • Muzzle swelling
  • Anaphylaxis

Precautions

​Handling Precaution:​ The vials are stable for several months once opened. Before use, shake gently to resuspend the product and continue to move the loaded syringe before injection to prevent precipitation.

Drug interactions

SpironolactoneMajor

Aldosterone antagonist; counteracts the effects of desoxycortone

FurosemideModerate

May excessively reduce potassium levels

ThiazidesModerate

May excessively reduce potassium levels

Monitoring

  • Serum sodium and potassium levels
  • Hydration status
  • Renal function parameters (BUN, Creatinine)
  • Clinical signs of Addison's relapse or overdosage (PU/PD)

Pharmacokinetics

Absorption

Slowly absorbed from the subcutaneous injection site providing long-acting effects.

Overdose

Overdoses may cause polyuria and hypokalaemia. Monitor electrolytes closely if overdose is suspected.

Available products

Formulations

  • Injectable: 25 mg/ml suspension for subcutaneous injection

Veterinary

  • Zycortal 25 mg/ml injectable suspension

Regulatory status

European Unionβœ“ ApprovedPrescription onlyEMA
πŸ• Dogs🐈 Cats

POM-V

United Kingdomβœ“ ApprovedPrescription onlyVMD
πŸ• Dogs🐈 Cats

POM-V

No regulatory data for: πŸ‡ΊπŸ‡Έ US Β· πŸ‡­πŸ‡° HK Β· πŸ‡ΉπŸ‡Ό TW Β· πŸ‡―πŸ‡΅ JP Β· πŸ‡°πŸ‡· KR Β· πŸ‡¦πŸ‡Ί AU

Storage & stability

Normal precautions should be observed. The vials, once opened, are stable for several months.

Client information

This medication is a long-term replacement therapy for your pet's missing hormones. ​Do not miss doses.​ Regular blood tests will be required to check electrolyte levels (sodium and potassium) to ensure the dose is exactly right for your pet. Contact your vet if you notice excessive drinking, excessive urination, vomiting, or lethargy.

VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.